Company profile

KAMADA LTD

NASDAQ:KMDABiotechnology: Pharmaceutical Preparations

Drug pipeline (5)

AssetStageRevenueTrialsStatus
CYTOGAMapproved—0—
HEPAGAM Bapproved—0—
KEDRABapproved—0—
VARIZIGapproved—0—
WINRHO SD, WINRHO SDF LIQUID, WINRHO SDF LYOPHILIZEDapproved—0—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (11)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT01217671phase2_3completed2009-12-012014-11-01Kamada, Ltd.International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema
NCT00499837phase2completed2007-09-012008-07-01Kamada, Ltd.Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients
NCT02005848phase2completed2014-04-012017-02-01Kamada, Ltd.Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes
NCT02001688phase2completed2014-04-012016-02-01Kamada, Ltd.Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"
NCT00460096phase2_3completed2007-03-01—Kamada, Ltd.Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency

FDA applications (5)

ApplicationApprovedTypeApplicantProducts
BLA 1256132017-08-23BLAKAMADA LTD.
BLA 1254302012-12-20BLAKAMADA LTD.
BLA 1250352006-01-27BLAKAMADA LTD.
BLA 1036491996-04-02BLAKAMADA LTD.
BLA 1031891990-04-17BLAKAMADA LTD.